CAR-T therapy for blood cancers: how do patients fare years later?
NCT ID NCT06906380
First seen Jan 07, 2026 · Last updated May 03, 2026 · Updated 24 times
Summary
This study follows up with 49 people who have relapsed acute myeloid leukemia or myelodysplastic syndrome and previously received ARD103 CAR-T cell therapy in an earlier trial. Researchers will monitor long-term side effects and overall survival to understand the lasting safety and effectiveness of the treatment. No new treatment is given; the goal is to gather important follow-up data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novant Health Cancer Institute
Charlotte, North Carolina, 28204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novant Health Cancer Institute
Winston-Salem, North Carolina, 27201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.